Organon & Co.
OGN- Exchange
- NYSE
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821825
No open-market purchases or sales by Organon & Co. insiders were filed in the last 90 days; 638 institutions reported holding it in 13F filings for Q2 2026, worth $2.92B in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Oct 31, 2026, 1:14 AM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 17, 2022 |
| Revenue | $6.22B | $6.40B | $6.26B | $6.17B | $6.30B |
| Cost of revenue | $2.90B | $2.69B | $2.52B | $2.29B | $2.38B |
| Gross profit | $3.31B | $3.71B | – | – | – |
| Research and development | $366.0M | $469.0M | $528.0M | $471.0M | $443.0M |
| Selling, general and administrative | $1.72B | $1.76B | $1.89B | $1.70B | $1.67B |
| Interest expense | $504.0M | $520.0M | $527.0M | $422.0M | $258.0M |
| Income tax | $238.0M | -$57.0M | -$350.0M | $205.0M | $178.0M |
| Net income | $187.0M | $864.0M | $1.02B | $917.0M | $1.35B |
| EPS, basic | $0.72 | $3.36 | $4.01 | $3.61 | $5.33 |
| EPS, diluted | $0.72 | $3.33 | $3.99 | $3.59 | $5.31 |
| Weighted shares, basic | 259.5M | 257.0M | 255.2M | 254.1M | 253.5M |
| Weighted shares, diluted | 260.8M | 259.2M | 256.3M | 255.2M | 254.2M |
| Margins and growth | |||||
| Gross margin | 53.3% | 58.0% | – | – | – |
| Net margin | 3.0% | 13.5% | 16.3% | 14.9% | 21.4% |
| Revenue growth, year over year | −2.9% | +2.2% | +1.4% | −2.1% | – |
| Net income growth, year over year | −78.4% | −15.5% | +11.6% | −32.1% | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 17, 2022 |
| Cash and equivalents | $574.0M | $675.0M | $693.0M | $706.0M | $737.0M |
| Accounts receivable | $1.33B | $1.36B | $1.74B | $1.48B | $1.38B |
| Inventory | $1.41B | $1.32B | $1.31B | $1.00B | $915.0M |
| Total current assets | $4.35B | $4.35B | $4.51B | $3.93B | $3.76B |
| Property, plant and equipment | $1.30B | $1.17B | $1.18B | $1.02B | $973.0M |
| Goodwill | $4.15B | $4.68B | $4.60B | $4.60B | $4.60B |
| Intangible assets | $1.13B | $1.41B | $533.0M | $649.0M | $651.0M |
| Total assets | $12.9B | $13.1B | $12.1B | $11.0B | $10.7B |
| Accounts payable | $952.0M | $1.15B | $1.31B | $1.13B | $1.38B |
| Short-term debt | $16.0M | $20.0M | $9.00M | $8.00M | $9.00M |
| Total current liabilities | $2.39B | $2.72B | $2.92B | $2.51B | $2.60B |
| Long-term debt | $8.63B | $8.86B | $8.75B | $8.90B | $9.13B |
| Total liabilities | $12.1B | $12.6B | $12.1B | – | – |
| Shareholders' equity | $752.0M | $472.0M | -$70.0M | -$892.0M | -$1.51B |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K/A | 10-K | 10-K | 10-K |
| Reported | Feb 12, 2026 | Feb 13, 2025 | Feb 15, 2024 | Feb 16, 2023 | Feb 17, 2022 |
| Operating cash flow | $700.0M | $939.0M | – | – | – |
| Capital expenditures | $162.0M | $175.0M | $251.0M | $196.0M | $192.0M |
| Free cash flow | $538.0M | $764.0M | – | – | – |
| Stock-based compensation | $77.0M | $105.0M | $101.0M | $75.0M | $59.0M |
| Dividends paid | $88.0M | $297.0M | $294.0M | $290.0M | $145.0M |
| Investing cash flow | -$390.0M | -$513.0M | – | – | – |
| Financing cash flow | -$561.0M | -$368.0M | – | – | – |
| Net change in cash | -$101.0M | -$18.0M | -$13.0M | -$31.0M | $667.0M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 1.2% | 1.6% | 1.6% | 1.2% | 0.9% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 23, 2026 | 262.6M | +1.0% | SEC |
| Jul 24, 2026 | 262.6M | +1.0% | SEC |
| Apr 27, 2026 | 262.6M | +1.0% | SEC |
| Feb 17, 2026 | 260.3M | +0.9% | SEC |
| Nov 3, 2025 | 260.0M | +0.9% | SEC |
| Jul 30, 2025 | 260.0M | +1.0% | SEC |
| Apr 25, 2025 | 260.0M | +1.1% | SEC |
| Feb 25, 2025 | 258.0M | +0.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.